Kymera Therapeutics (KYMR) Misses Q2 EPS by 3c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.67), $0.03 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $16.51 million versus the consensus estimate of $13.93 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• ManpowerGroup (MAN) Reports In-Line Q3 EPS; offers guidance
• Home Bancshares (HOMB) Tops Q3 EPS by 1c
• Nickel 28 to receive $4.4M distribution from Ramu joint venture